Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5Terminated 4Suspended 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Breast Neoplasms 2HER-2 Positive Advanced Gastric Cancer 1Advanced Solid Tumor 1Advanced Solid Malignancies 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × HM781-36B × Clear all
NCT02659514 2022-03-11

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
67 enrolled 16 charts
Breast

Breast Neoplasms

NCT02418689 2022-01-20

Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens

Hanmi Pharmaceutical Company Limited

Phase 2 Completed
106 enrolled
Breast

Breast Neoplasms

NCT01746771 2016-03-03

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

Hanmi Pharmaceutical Company Limited

Phase 1/2 Completed
44 enrolled
Gastrointestinal

HER-2 Positive Advanced Gastric Cancer

NCT01455571 2014-02-26

Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors

Hanmi Pharmaceutical Company Limited

Phase 1 Completed
55 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT01455584 2013-05-23

Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors

Hanmi Pharmaceutical Company Limited

Phase 1 Completed
20 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡